Phase III PEMPHIX study showed that Roche ’s Mabthera/Rituxan (rituximab) is superior to standard of care in achieving sustained remission in patients with pemphigus vulgaris
Roche today announced positive topline results from the Roche-sponsored phase III PEMPHIX study, evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Investor Update)
Source: Roche Investor Update - June 13, 2019 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Mabthera/Rituxan (rituximab) in children with two rare blood vessel disorders
Roche announced today that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for the use of MabThera®/Rituxan® (rituximab), in combination with glucocorticoids (GCC), for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children two years of age a nd older. (Source: Roche Investor Update)
Source: Roche Investor Update - June 12, 2019 Category: Pharmaceuticals Source Type: news

Polivy Chemoimmunotherapy Regimen Approved to Treat DLBCL
TUESDAY, June 11, 2019 -- Polivy (polatuzumab vedotin-piiq), a novel antibody-drug conjugate, received approval to treat patients with diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab, the U.S. Food and Drug... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 11, 2019 Category: General Medicine Source Type: news

FDA grants Roche ’s Polivy accelerated approval for people with previously treated aggressive lymphoma
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy ™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies. (Source: Roche Media News)
Source: Roche Media News - June 11, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Polivy accelerated approval for people with previously treated aggressive lymphoma
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy ™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies. (Source: Roche Investor Update)
Source: Roche Investor Update - June 11, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Polatuzumab Yedotin-Piiq Combination for DLBCL Patients
The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate, in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Erin Kayata Source Type: news

FDA Approves Polatuzumab Vedotin-Piiq Combination for DLBCL Patients
The FDA granted accelerated approval to polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate, in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Erin Kayata Source Type: news

Chemoimmunotherapy Regimen Approved to Treat DLBCL
MONDAY, June 10, 2019 -- Polivy (polatuzumab vedotin-piiq), a novel antibody-drug conjugate, received approval to treat patients with diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab, the U.S. Food and Drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2019 Category: Pharmaceuticals Source Type: news

FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma
Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma. (Source: World Pharma News)
Source: World Pharma News - June 10, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Cladribine Plus Upfront Rituximab Shows Promise in Hairy Cell Leukemia
Researchers tested simultaneous vs delayed rituximab with cladribine in patients with hairy cell leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Did Rituximab Maintenance Add Benefit for DLBCL After R-CHOP?
Maintenance rituximab was tested in patients with diffuse large B-cell lymphoma who achieved complete remission after R-CHOP. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
(University of Texas M. D. Anderson Cancer Center) Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2019 Category: International Medicine & Public Health Source Type: news

Lenalidomide + Rituximab Beneficial in Relapsed/Refractory Non-Hodgkin Lymphoma
The MAGNIFY phase IIIb trial looked at the efficacy and safety of lenalidomide combined with rituximab in  relapsed/refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Podcast: Immunosuppressive treatment for people with proliferative lupus nephritis
Systemic lupus erythematosus, or SLE, is an autoimmune disease that can affect any part of the body. About half the people with it develop lupus nephritis. In the June 2018 update of their Cochrane Review, David Tunnicliffe from the Centre for Kidney Research in the Children ’s Hospital at Westmead and the University of Sydney’s School of Public Health in Australia and colleagues brought together the studies that have tested a range of treatments." Lupus nephritis is a serious condition, leading to end-stage kidney disease in 15% of patients after 10 years. It mainly affects women of child-bearing age, and is more comm...
Source: Cochrane News and Events - May 30, 2019 Category: Information Technology Authors: Lydia Parsonson Source Type: news

FDA Approves Combo for Indolent Non-Hodgkin Lymphomas FDA Approves Combo for Indolent Non-Hodgkin Lymphomas
Lenalidomide may now be used in combination with rituximab for previously treated follicular lymphoma and previously treated marginal zone lymphoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 29, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news